Anatomical Pathology Special Stains and Immunohistochemistry
RCPAQAP myQAP login Data Analysis

NKX3.1

Platform
Roche Ventana Benchmark Ultra
Clone/manufacturer
EP356 (760-5086 - Roche Ventana)
Antibody dilution
Predilute
Antibody incubation time/temp
16 mins at 36°C
Antigen retrieval buffer time/temp
Ventana CC1 32 mins at 100°C
Amplification
Not applicable
Detection kit
760-700 Ventana OptiView
Program (mark)
General 2019 (5/5)

NKX3.1 is a prostate‑specific, androgen‑regulated nuclear transcription factor essential for normal prostatic epithelial and ductal development. In IHC it shows strong nuclear staining and serves as a highly sensitive and specific marker for identifying tumours of prostatic origin, including metastatic prostate adenocarcinoma. Loss or reduction of NKX3.1 expression is common in prostate carcinoma and high‑grade PIN due to allelic loss, promoter methylation, or post‑transcriptional silencing. Because of its high specificity compared to other prostate markers, NKX3.1 is valuable in confirming prostatic lineage in metastatic lesions of uncertain origin (1).

Recommended Controls

Criteria for acceptable staining is a nuclear staining pattern. The recommended positive control is to include a prostate cancer (high expressor). Testes will show a weak to moderate staining reaction in the spermatogonia (low expressor) and tonsil or appendix which will be negative.

Expected staining pattern


Prostate cancer


Testes

Disclaimer

These methods are intended as a guide only. Laboratories that wish to implement these methods should perform internal validation/verification prior to use. The RCPAQAP does not make any claim or warranty for the accuracy or performance of these methods.

References
  1. Thakur S, Enwere E. NKX3.1. PathologyOutlines.com website. https://www.pathologyoutlines.com/topic/stainsnkx3.html.

  2. Images of prostate cancer and normal testes_QAP survey results

Last updated on March 05, 2026
Back to top
en_AUEnglish
It appears you're using an old version of Internet Explorer for safer and optimum browsing experience please upgrade your browser.